REGN
$REGN
Regeneron Pharmaceuticals
Biotech company known for Eylea and Dupixent immunology drugs.
HealthcareSubscribers
0
Tracking this ticker
Next Report
—
Weekly updates
Latest Report
REGN: EYLEA Update and Earnings Momentum (REGN)
Regeneron (REGN) benefits from FDA label expansion for extended EYLEA HD dosing and a strong analyst consensus. Upcoming Q1 results and tariff headlines create near-term volatility but the longer-term growth outlook remains constructive.
Apr 6, 2026